Morbid Obesity, Thromboembolism, Bypass Complications
Conditions
Keywords
Nadroparin, Anti-Xa activity
Brief summary
This study is a prospective evaluation of the relationship between lean body weight and anti-Xa activity and 5700 International Units (IU) nadroparin 4 hours after subcutaneous administration in morbidly obese patients after bariatric surgery.
Detailed description
There is no guideline for postoperative thromboembolic prevention in morbidly obese patients. The investigators goal is to examine which dose of nadroparin is effective.
Interventions
DRUGNadroparin
Patients receive before surgery 3 days 2850 IU nadroparin. anti-Xa levels will be measured. After surgery they receive 5700 IU for 4 weeks as standard care in our hospital. 3 days and 4 weeks after surgery anti-Xa levels will be measured again.
Sponsors
Rijnstate Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Approval for Roux-en-Y gastric bypass * Total body weight \> 140 kg
Exclusion criteria
* Renal impairment (GFR \< 30ml/min and/ or serum creatinin \> 150 micromol/ml) * Coagulation disorders * Use of vitamin K antagonists (such as acenocoumarol) pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| anti-Xa activity 4 hours after subcutaneous administration of 5700 IU nadroparin | 4 hours |
Countries
Netherlands
Contacts
Primary ContactWendy Schijns, MD
Outcome results
None listed